Al Bentley
5 min read
AI related risks just jumped to the top of the Federal Reserve’s financial stability worries, with a surge in complex debt tied to AI infrastructure. That kind of boom and scrutiny can push investors to look at other cutting edge areas. Carefully chosen biotech stocks with solid balance sheets can offer a different source of potential high upside. This article walks through three such biotech opportunities from our US screener.
The three biotech stocks covered below are only a small sample from the idea, and the full screen surfaced 86 more companies with equally compelling stories that are not covered in this article.
To identify your own high conviction biotech setups, go straight to the Biotech Stocks screener to filter and analyze the full list based on the factors that matter most to you.
Amgen (AMGN)
Amgen is a large biotech player focused on discovering and commercializing human therapeutic biologics. It generated about US$38.9b from human therapeutics in 2024, and with a market value around US$252.6b it brings scale to a sector where balance sheet strength matters.
For biotech investors who want exposure to commercially proven therapies rather than early stage concepts, Amgen offers a broad portfolio of biologic drugs that ties directly to the Biotech Stocks screener theme. According to DKDGI, an investor in the Simply Wall St Community, one key question is how the group funds that pipeline without stretching its finances.
“Dividend covered about 2x by free cash flow; debt from the Horizon deal is being paid down.”
What happens to that careful balance if one unseen pressure on future cash generation moves in the wrong direction?
If that risk feels underpriced to you, read the full narrative for Amgen to see how Amgen’s cash engine could accelerate or stall under different stress tests.
Vertex Pharmaceuticals (VRTX)
Vertex Pharmaceuticals is closely aligned with the Biotech Stocks theme through its cystic fibrosis and rare disease medicines. The analyst consensus Narrative on Simply Wall St highlights the potential in how that cash engine funds a new wave of high risk, high reward kidney programs.
“Expansion of the renal disease portfolio, including late stage programs like povetacicept in IgA nephropathy, with what management describes as best in class numerical reductions in proteinuria and favorable auto injector dosing, and inaxaplin in APOL1 mediated kidney disease, with significant UACR reductions and an interim 1 year eGFR readout planned in early 2027, is supported by growing regulatory acceptance of proteinuria and 1 year eGFR endpoints.”
